{"id":390551,"date":"2018-11-15T00:00:00","date_gmt":"2018-11-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0002-2018-biopharma-unipolar-depression-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-16T11:25:41","modified_gmt":"2026-04-16T11:25:41","slug":"dlsfcg0002-2018-biopharma-unipolar-depression-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0002-2018-biopharma-unipolar-depression-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Unipolar Depression | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p>Unipolar depression\u2019s very\u00a0crowded generic therapy market makes it a challenge for branded agents to gain a strong foothold.\u00a0<abbr title=\"selective serotonin reuptake inhibitor\">SSRI<\/abbr>s\u2019 use as first-line treatments and continued position as the patient-share leaders contribute to the challenges that branded therapies face entering this market. However, the need for effective treatments that address the symptoms of the one-third of depression patients who are treatment-resistant is expected to drive growth as newer-to-market therapies (e.g., Lundbeck\/Otsuka Pharmaceutical\u2019s Rexulti\/RXulti, Allergan\u2019s Vraylar) are incorporated into the treatment paradigm and as emerging therapies targeting underserved cohorts of depression patients (e.g., Janssen\u2019s esketamine, Allergan\u2019s rapastinel, Alkermes\u2019s ALKS-5461) enter the market.<\/p>\n<p><strong>QUESTIONS ANSWERED:<\/strong><\/p>\n<ul>\n<li>What factors drive and constrain the use of branded antidepressants and atypical antipsychotics for the treatment of unipolar depression? What branded therapy is expected to experience the greatest commercial success during the 2017-2027 forecast period?<\/li>\n<li>Given the crowded and highly genericized unipolar depression market, what is the commercial potential of key late-phase emerging therapies for unipolar depression?<\/li>\n<li>What are the greatest areas of unmet need in the treatment of unipolar depression, and how are the emerging therapies expected to address these unmet needs?<\/li>\n<li>Therapies with a more-rapid onset of action are a substantial unmet need in the treatment of unipolar depression. To what extent will emerging therapies, such as Janssen\u2019s esketamine, Allergan\u2019s rapastinel, and Alkermes\u2019s ALKS-5461, capitalize on this unmet need? How will physicians likely incorporate these treatments into their clinical practice?<\/li>\n<\/ul>\n<p><strong>Markets covered:\u00a0<\/strong>United States, France, Germany, Italy, Spain, United Kingdom, Japan<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Approximately 20 country-specific interviews with thought-leading psychiatrists and\u00a0<abbr title=\"primary care physician\">PCP<\/abbr>s\/<abbr title=\"general practitioner\">GP<\/abbr>s; supported by survey data collected for this and other\u00a0<abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0research.<\/p>\n<p><strong>Epidemiology:\u00a0<\/strong>12-month prevalence of unipolar depression by country, segmented by\u00a0<abbr title=\"major depressive disorder\">MDD<\/abbr>, minor depression, and dysthymia; diagnosed and drug-treated cases of unipolar depression; 12-month prevalence of\u00a0<abbr title=\"major depressive disorder\">MDD<\/abbr>\u00a0by country, segmented by chronic pain status; 12-month prevalence of\u00a0<abbr title=\"major depressive disorder\">MDD<\/abbr>\u00a0by country, segmented by treatment-resistant status.<\/p>\n<p><strong>Emerging therapies:\u00a0<\/strong>Phase II: 19 drugs; Phase III: 3 drugs; preregistration: 4 drugs. Coverage of 18 select preclinical and Phase I products.<\/p>\n<p><strong>Market forecast features:\u00a0<\/strong>Patient-based market forecast extending from 2017 through 2027.<\/p>\n<p><strong>Key companies:\u00a0<\/strong>Allergan, Alkermes, AstraZeneca, Axsome Therapeutics, Fabre-Kramer, Gedeon Richter, GlaxoSmithKline, Janssen, Lundbeck, Otsuka Pharmaceutical, Pfizer, Sage Therapeutics, Shionogi, Sumitomo Dainippon, Sunovion<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Aripiprazole, bupropion HCl\u00a0<abbr title=\"sustained release\">SR<\/abbr>\/<abbr title=\"extended release\">XR<\/abbr>, duloxetine, escitalopram, Latuda (lurasidone), quetiapine\u00a0<abbr title=\"immediate release\">IR<\/abbr>\/<abbr title=\"extended release\">XR<\/abbr>, venlafaxine\u00a0<abbr title=\"immediate release\">IR<\/abbr>\/<abbr title=\"extended release\">XR<\/abbr>, Rexulti\/RXulti (brexpiprazole), Trintellix\/Brintellix (vortioxetine), Vraylar (cariprazine), ALKS-5461,\u00a0ASC-01, AXS-05, esketamine, gepirone\u00a0<abbr title=\"extended release\">ER<\/abbr>, rapastinel, SAGE-217<\/p>\n","protected":false},"template":"","class_list":["post-390551","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-unipolar-depression","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390551\/revisions"}],"predecessor-version":[{"id":393675,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390551\/revisions\/393675"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}